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Initiation of an Abacavir-Containing Regimen in HIV-Infected
Adults Is Associated with a Smaller Decrease in Inflammation
and Endothelial Activation Markers
Compared to Non-Abacavir-Containing Regimens
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Abstract
Abacavir has been associated with myocardial infarction in several studies. This may be related to inflammation
and endothelial cell activation. We compared changes in inflammation and endothelial activation markers
between antiretroviral-naive adults initiating zidovudine, lamivudine, abacavir, and nonnucleoside reverse
transcriptase inhibitor (NNRTI) or this regimen without abacavir. Changes in soluble tumor necrosis factor
receptors-I, -II (sTNFR-I, -II), high sensitivity C-reactive protein, and soluble vascular cell adhesion molecule-1
(sVCAM-1) from baseline (pre-ART) to a second time point about 24 weeks after initiating antiretroviral therapy
(ART) were compared between groups using multivariable linear regression. A total of 37 met eligibility criteria;
12 received abacavir. The median (interquartile range) age was 37 years (27–45). Most were men (32/37),
African-American (15/37), or white (15/37). The median nadir CD4 + and baseline HIV-1 RNA were 230 cells/
mm3 (180–301) and 82,642 copies/ml (34,400–204,703). In all, 15/30 smoked, 7/37 had hypertension, 1/37 had
diabetes, and 1/37 had hyperlipidemia. None had coronary or renal disease. Changes in CD4 + and HIV-1 RNA
level and timing of stored samples with regard to ART initiation were not different between groups. In univariable
analysis, log transformed percent change in sTNFR-I ( p = 0.05) and -II ( p = 0.04) showed significant between-group
differences and trended toward significance for sVCAM-1 ( p = 0.08). These markers decreased less in the abacavir
group. After adjustment for confounders, significantly less decrease for sTNFR-II and sVCAM-1 was seen for those
receiving the abacavir-containing regimen. When taken with an NNRTI, abacavir induced a smaller decrease in
inflammation biomarkers in this cohort, suggesting a possible proinflammatory effect of this nucleoside analogue.
In 2008, the D:A:D Study Group published the results of acohort study of HIV-infected adults in which recent use of
abacavir was associated with myocardial infarction (MI) with
an adjusted rate ratio of 1.90 (95% CI 1.47–2.45).1 This result
has been reproducible in some,2–5 but not all studies6–11 and a
question of biological plausibility persists.
We performed a retrospective cohort study utilizing the
Center for AIDS Research (CFAR) sample repository and
clinical database. HIV-1-infected adults, antiretroviral-naive
at study entry who initiated a regimen of zidovudine (AZT),
lamivudine (3TC), abacavir (ABC), and a nonnucleoside re-
verse transcriptase inhibitor (NNRTI) or the same regimen
without ABC after 1997 were included. Participants also had
to have a plasma sample stored within 6 months prior to
initiating antiretroviral therapy (ART) as well as 3–9 months
after starting that same unchanged regimen and a signed in-
formed consent to allow their stored samples to be used for
HIV-related research. Participants were excluded if pregnant
when ART was initiated, had an active opportunistic infection
(OI), or had an HIV-1 RNA level > 400 copies/ml when the
second sample was stored. This study was approved by the
University Hospitals Case Medical Center and University of
North Carolina Institutional Review Boards.
Previously stored samples were tested for markers of in-
flammation [soluble tumor necrosis factor alpha receptors
(sTNFR-I and -II) and high-sensitivity C-reactive protein
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(hs-CRP)] and endothelial activation [soluble vascular cell
adhesion molecule-1 (sVCAM-1)] from before starting ART
and 3–9 months later. Biomarkers with compelling data
linking them to CVD risk, and especially those known to be
elevated in HIV patients, were selected. Elevated hs-CRP has
been associated with subclinical atherosclerosis and is inde-
pendently predictive of future cardiovascular disease events
in both the general population and in HIV.12,13 The inflam-
matory marker tumor necrosis factor-a (TNF-a) has been im-
plicated in MI after acute coronary syndromes and levels have
been shown to be higher in patients who subsequently ex-
perience recurrent MIs or cardiac death.14,15 The effects of
TNF-a are mediated by two receptors, sTNFR-I and sTNFR-II.
These soluble receptors are stable in serum, easily measured,
and reflect activity of TNF-a. Likewise, sVCAM-1 arises from
shedding or proteolytic cleavage from activated endothelial
cells and is a useful marker for increased activation of endo-
thelial cells in atherosclerosis.16–18 All markers were measured
using a commercially available enzyme-labeled immunosor-
bent sandwich assay at Aushon Biosystems, Billerica, MA.
Tests were done in duplicate and averaged. For sTNFR-I,
sTNFR-II, hs-CRP, and sVCAM-1, the median intraassay and
interassay coefficients of variation were 8.8% and 10.8%, 8.6%
and 6.0%, 6.9% and 4.5%, and 8.7% and 13.4%, respectively.
Demographic, HIV and cardiovascular characteristics, in-
flammatory and endothelial markers are described using
median and interquartile range (IQR) for continuous variables
and frequency and percent for categorical variables. Changes
in the markers are reported as absolute and log-transformed
percent change from baseline [loge(percent change from
baseline + 1)]. Differences within and between groups were
tested using paired and unpaired Student’s t-tests or Wil-
coxon signed rank or rank sum tests as distributionally ap-
propriate for continuous variables. Fisher’s exact tests or exact
Pearson Chi square tests were used for between-group com-
parisons as appropriate for categorical variables. All tests
were two-sided with a type I error of 0.05. For confounding
adjustment, univariable followed by multivariable linear re-
gression was performed with log-transformed percent change
in each marker as the dependent variable. Multivariable
models were created by including ART treatment group,
duration of time between starting ART and second sample,
and baseline CD4 + count, and those variables found to be
statistically associated with the outcome in univariable anal-
ysis at p £ 0.05. Backward elimination by least significant
variable was used for model selection (ART treatment group
and duration to second sample were left in the model re-
gardless of significance). Once models were created in this
way, each variable tested in univariable analysis was added in
turn to see if the regression coefficient estimate for ART
treatment group changed by ‡ 10%. Final models were tested
to be sure the assumptions of linear regression were met. All
statistical analyses were performed using SAS version 9.2
(The SAS Institute, Cary, NC).
Thirty-seven patients met eligibility criteria: 12 in the
ABC group and 25 in the control (non-ABC) group. Overall,
most were men (86%), and African-American (41%) or white
(41%). Median nadir and baseline CD4 + counts (cells/mm3)
were 230 (180–301) and 244 (180–316), respectively. Median
baseline HIV-1 RNA level (copies/ml) was 82,642 (34,400–
204,703). Median known duration of HIV prior to ART initi-
ation (years) was 0.6 (0.2–1.2) and median year ART initiated
was 2002 (2000–2003). Fifty percent (15/30) were current
smokers. Out of the 37 participants, seven had hypertension,
one had diabetes mellitus, one had hyperlipidemia, and none
had coronary artery disease. The median body mass index
(kg/m2) was 26.3 (25.2–27.2). The median creatinine (mg/dl)
was 0.9 (0.8–1.0). Three percent (1/32) used intravenous
drugs. The majority (26/37) received care at Case Western
Reserve.
There were no statistically significant differences between
groups with regard to the change in CD4 + cell count or HIV-1
RNA level over the study period ( p = 0.84 and p = 0.91, re-
spectively). By design (as indirect reflection of good adher-
ence to ART), all participants had HIV-1 RNA £ 400 copies/ml
at the time of the second biomarker measurement point. In the
ABC group, 10/12 had HIV-1 RNA £ 50 copies/ml and in
the control group, 13/25 had HIV-1 RNA £ 50 copies/ml.
Baseline demographic and clinical characteristics were similar
between groups, although age trended toward being signifi-
cantly lower for the ABC group [median age (years) for con-
trols was 38 (32–48) vs. 31 (27–35) for the ABC group
( p = 0.06)].
Sample storage dates ranged from April 14, 1999 to No-
vember 20, 2008 and the timing of the stored samples with
regard to ART initiation was not different between groups
( p = 0.43 and p = 0.2 between groups for the first and second
sample, respectively). The overall median times between the
first sample and starting ART and duration on ART before the
second sample (months) were 0.5 (0–1.3) and 5.6 (4.8–5.9),
respectively.
Baseline, absolute change, and log-transformed percent
change in the markers over the study period are shown in
Table 1 with results of between- and within-group analyses.
In the control group, all markers appeared to improve, with
changes in sTNFR-I, sTNFR-II, and sVCAM-1 reaching sta-
tistical significance (all p < 0.001). In the ABC group, sTNFR-II
significantly improved ( p = 0.05). Between groups, differences
in the change in sTNFR-I and sTNFR-II were statistically
significant and change in sVCAM-1 neared significance. After
adjustment, the ART treatment group remained indepen-
dently associated with changes in sTNFR-II and sVCAM-1.
For both of these markers, there was a greater degree of im-
provement in the control group when compared to the ABC
group.
In this study we compared changes in several markers of
inflammation and endothelial activation between ART-naive
adults starting AZT/3TC/ABC + NNRTI or the same regi-
men without ABC. After adjustment for factors known to
affect inflammation, sTNFR-II and sVCAM-1 decreased less
in the group taking ABC. As such, it is possible that the on-
going heightened inflammation and endothelial activation
occurring while on ABC contribute to risk of myocardial in-
farction observed in some studies. Although not congruent
across all studies,19–24 this notion that ABC may lead to a
higher degree of inflammation is supported by other research.
The SMART/INSIGHT investigators showed that hs-CRP
and IL-6 levels were higher in those SMART study partici-
pants receiving ABC.2 In ART-experienced participants
switching to either an ABC-containing regimen or another
NRTI, Kristoffersen et al. showed that matrix metallopepti-
dase 9, myeloperoxidase, and hs-CRP increased in the group
changed to ABC.25 Also, De Pablo et al. showed that ABC
induces an interaction between human leukocytes and
1562 HILEMAN ET AL.
endothelial cells in a dose-dependent fashion through acti-
vation of Mac-1, which interacts with ICAM-1.26
Major limitations of this study include the retrospective
observational study design in which ART allocation was not
randomized and the small sample size. Because of this, we
attempted to minimize the effect of confounding by restricted
eligibility, excluding those pregnant and with active infec-
tious/inflammatory conditions and by adjusting for factors
determined or known to confound the relationship between
ART group and the outcome. However, unmeasured con-
founding cannot be excluded as an explanation for the results
that we obtained. Other limitations include having only one
biomarker measurement after ART initiation and not having
data on HLA-B5701 status for the participants. Having re-
peated measures would have better characterized changes in
these markers over time. However, in choosing a time point
on average 6 months after ART initiation and after partici-
pants had become virologically suppressed, we hoped to be
measuring these markers at a point when the levels would be
stable, i.e., after a period of expected improvement. Also, not
having data on HLA-B5701 status limits our ability to exclude
possible subclinical or early abacavir hypersensitivity reaction
as a reason for the results that we obtained. However, we did
thoroughly evaluate the data for outliers with regard to the
biomarkers measured and did not find a subgroup.
In conclusion, in the setting of NNRTI treatment, there was
a smaller decrease in sTNFR-II and sVCAM-1 after adjust-
ment for important confounders in the group that included
ABC. This suggests that chronic heightened inflammation
may play a role in the increased risk of MI observed in some
studies with ABC.
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